Table 1.
Baseline characteristics of the study population
| Clinical characteristics | Overall population | Non-survivors | Survivors | P- value |
|---|---|---|---|---|
| (n = 1148) | (n = 138) | (n = 1010) | ||
| Age, years | 67.2 ± 6.9 | 70.9 ± 6.9 | 66.7 ± 6.8 | < 0.001 |
| Male | 654 (57.0) | 82 (59.4) | 572 (56.6) | 0.535 |
| BMI, kg/m2 | 25.4 ± 2.8 | 25.7 ± 2.8 | 25.4 ± 2.8 | 0.321 |
| Duration of diabetes, years | 10.0(4.0–15.0) | 9.5(4.8–14.3) | 10.0 (4.0–15.0) | 0.780 |
| Smoker | 471 (41.0) | 68 (49.3) | 403 (39.9) | 0.036 |
| Hypertension | 934 (81.4) | 123 (89.1) | 811 (80.3) | 0.012 |
| Family history of CAD | 118 (10.3) | 14 (10.1) | 104 (10.3) | 0.956 |
| Previous MI | 176 (15.3) | 31 (22.5) | 145 (14.4) | 0.013 |
| Previous PCI | 245 (21.3) | 26 (18.8) | 219 (21.6) | 0.445 |
| Previous CABG | 68 (5.9) | 10 (7.2) | 58 (5.7) | 0.483 |
| Previous stroke | 294 (25.6) | 47 (34.1) | 247 (24.5) | 0.015 |
| Clinical presentation | 0.195 | |||
| SAP | 293(25.5) | 29(21.0) | 264 (26.1) | |
| ACS | 855(74.5) | 109(79.0) | 746 (73.9) | |
| LVEF | 58(52–62) | 56(45–60) | 58 (54–62) | < 0.001 |
| Laboratory findings | ||||
| Hemoglobin, g/dl | 131.0 ± 18.9 | 126.9 ± 19.7 | 131.5.1 ± 18.7 | 0.007 |
| FPG, mmol/L | 8.0 ± 3.1 | 9.4 ± 3.8 | 7.8 ± 2.9 | < 0.001 |
| HbA1c, % | 7.7 ± 1.4 | 7.8 ± 1.4 | 7.7 ± 1.5 | 0.559 |
| SHR | 0.87 ± 0.40 | 1.02 ± 0.48 | 0.85 ± 0.38 | < 0.001 |
| TC, mmol/L | 4.48 ± 1.20 | 4.29 ± 1.10 | 4.51 ± 1.21 | 0.041 |
| TG, mmol/L | 1.54(1.14–2.08) | 1.35(1.06–1.90) | 1.56(1.15–2.11) | 0.014 |
| HDL-C, mmol/L | 1.03 ± 0.29 | 0.99 ± 0.27 | 1.04 ± 0.29 | 0.089 |
| LDL-C, mmol/L | 2.98 ± 1.00 | 2.84 ± 0.93 | 3.00 ± 1.02 | 0.084 |
| hs-CRP, mg/L | 2.16(0.82–5.96) | 3.82(0.94–13.50) | 2.03(0.81–5.38) | 0.001 |
|
NT-proBNP, pg/ml Creatinine(umol/l) |
232.0 (97.6–895.1) | 839.8 (230.0–2414.5) | 201.1 (88.9–712.5) | < 0.001 |
| < 0.001 | ||||
| Three-vessel disease | 75.5 ± 27.4 | 86.3 ± 31.9 | 74.0 ± 26.4 | 0.058 |
| Left main disease | 856 (74.6) | 112 (81.2) | 744 (73.7) | 0.024 |
| Treatment | 154 (13.4) | 27 (19.6) | 127 (12.6) | 0.498 |
| Medicine treatment | ||||
| PCI | 271 (23.6) | 37 (26.8) | 234 (23.2) | |
| CABG | 701 (61.1) | 78 (56.5) | 623 (61.7) | |
| Medications at discharge | 176 (15.3) | 23 (16.7) | 153 (15.1) | |
| Aspirin | 0.120 | |||
| Clopidogrel/Ticagrelor | 1117 (97.3) | 131 (94.9) | 986 (97.6) | 0.896 |
| β-blocker | 1011 (88.1) | 122 (88.4) | 889 (88.0) | 0.864 |
| ACEI/ARB | 781 (68.0) | 93 (67.4) | 688 (68.1) | 0.625 |
| Statin | 660 (57.5) | 82 (59.4) | 578 (57.2) | 0.018 |
| Insulin | 1100 (95.8) | 127 (92.0) | 973 (96.3) | 0.689 |
| 481 (41.9) | 60 (43.5) | 421 (41.7) | ||
Data are expressed as mean ± SD, medians with interquartile ranges or percentage. BMI body mass index, CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, SAP stable angina pectoris, ACS acute coronary syndrome, LVEF left ventricle ejection fraction, FPG fasting plasm glucose, HbA1c Hemoglobin A1c, SHR stress hyperglycemia ratio, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hs‐CRP high‐sensitivity C‐reactive protein, NT-proBNP N-terminal proB-type natriuretic peptide, ACEI angiotensin II coenzyme inhibitor, ARB angiotensin II receptor blocker